Literature DB >> 15769637

The role of interleukin-2 receptor alpha in cancer.

Deborah J Kuhn1, Q Ping Dou.   

Abstract

Interleukin-2 (IL-2) is the major growth factor for activated T-lymphocytes and stimulates clonal expansion and maturation of these lymphocytes. IL-2 binds to its receptor complex, IL-2Ralpha, beta, and gamma chains, and exerts its effect via second messengers, mainly tyrosine kinases, which ultimately stimulate gene expression. The heterotrimerization of the receptor chains leads to high affinity binding for IL-2. The functional importance of IL-2Ralpha in hematopoietic cell systems is well known. However, the potential role that IL-2Ralpha plays in tumorigenesis is still not fully elucidated. Il-2Ralpha expression has been found in many types of cancers, including leukemia, lymphoma, lung, breast, head-and-neck and prostate. Recent evidence shows that high expression of IL-2Ralpha in tumors correlates with a poor prognosis for the patient. This review details the current known functions of IL-2Ralpha in cancer cells and some of the therapies used to combat IL-2Ralpha-mediated cell signaling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15769637     DOI: 10.2741/1631

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  15 in total

1.  Elevated serum soluble interleukin-2 receptor levels increase malignancy-related risk in patients on chronic hemodialysis.

Authors:  Chen XiaoHong; Shen Bo; Xiang FangFang; Guo Man; Zou JianZhou; Liu ZhongHua; Lv WenLv; Cao XueSen; Ding XiaoQiang; Zhang Boheng
Journal:  Int J Clin Oncol       Date:  2019-06-10       Impact factor: 3.402

2.  IL-2 and IFN-gamma in the retina of diabetic rats.

Authors:  Siv Johnsen-Soriano; María Sancho-Tello; Emma Arnal; Amparo Navea; Enrique Cervera; Francisco Bosch-Morell; Maria Miranda; Francisco Javier Romero
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-03-06       Impact factor: 3.117

3.  Genetic variants in interleukin genes are associated with breast cancer risk and survival in a genetically admixed population: the Breast Cancer Health Disparities Study.

Authors:  Martha L Slattery; Jennifer S Herrick; Gabriella Torres-Mejia; Esther M John; Anna R Giuliano; Lisa M Hines; Mariana C Stern; Kathy B Baumgartner; Angela P Presson; Roger K Wolff
Journal:  Carcinogenesis       Date:  2014-03-26       Impact factor: 4.944

4.  Serum cytokine analysis in a positive chemoprevention trial: selenium, interleukin-2, and an association with squamous preneoplastic disease.

Authors:  Mark J Roth; Hormuzd A Katki; Wen-Qiang Wei; You-Lin Qiao; Rachel Bagni; Guo-Qing Wang; Denise Whitby; Zhi-Wei Dong; Mitchell H Gail; Paul J Limburg; Carol A Giffen; Philip R Taylor; Sanford M Dawsey
Journal:  Cancer Prev Res (Phila)       Date:  2010-06-29

5.  Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia.

Authors:  Beverly J Lange; Richard K Yang; Jacek Gan; Jaquelyn A Hank; Eric L Sievers; Todd A Alonzo; Robert B Gerbing; Paul M Sondel
Journal:  Pediatr Blood Cancer       Date:  2011-06-16       Impact factor: 3.167

Review 6.  The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy.

Authors:  Thomas A Waldmann
Journal:  Cancer Immunol Res       Date:  2015-03       Impact factor: 11.151

7.  Impact of genetic variants in IL-2RA and IL-2RB on breast cancer risk in Chinese Han women.

Authors:  Lingge He; Wenjie Zhang; Shuangyu Yang; Wenting Meng; Xia Dou; Jianfeng Liu; Yuanwei Liu; Haiyue Li; Tianbo Jin
Journal:  Biochem Genet       Date:  2021-01-28       Impact factor: 1.890

8.  T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies.

Authors:  Camilla A Lindqvist; Lisa H Christiansson; Bengt Simonsson; Gunilla Enblad; Ulla Olsson-Strömberg; Angelica S I Loskog
Journal:  Immunology       Date:  2010-11       Impact factor: 7.397

9.  Efficiency of immunotoxin cytotoxicity is modulated by the intracellular itinerary.

Authors:  Lori L Tortorella; Nina H Pipalia; Sushmita Mukherjee; Ira Pastan; David Fitzgerald; Frederick R Maxfield
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

10.  Sam68 modulates the promoter specificity of NF-κB and mediates expression of CD25 in activated T cells.

Authors:  Kai Fu; Xin Sun; Wenxin Zheng; Eric M Wier; Andrea Hodgson; Dat Q Tran; Stéphane Richard; Fengyi Wan
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.